The Netherlands Cancer Institute: Colorectal Neoplasms trials

The registry lists 13 Colorectal Neoplasms studies with The Netherlands Cancer Institute as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 7Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic TherapyRecruitingNCT06857773Phase 3
• LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsRecruitingNCT06012734Phase 1
• FAPI PET/CT for Lymph Node Staging in Colorectal CarcinomaRecruitingNCT05209750Not applicable
• Galunisertib Combined With Capecitabine in Advanced CRC With PMActive, not recruitingNCT05700656Phase 1/2
• Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal CancersActive, not recruitingNCT05131919Phase 2
• Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)Status unknownNCT04552093Phase 2/3
• Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal CancerStatus unknownNCT04231175Not applicable
• Diagnostic Yield of Colonoscopy Surveillance in Testicular Cancer Survivors Treated With Platinum-based ChemotherapyCompletedNCT04180033Not applicable
• Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerWithdrawnNCT03470350Phase 1/2
• Molecular Stool Testing for Colorectal Cancer SurveillanceCompletedNCT02715141
• Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
• Lapatinib Plus Trametinib in KRAS Mutant NSCLCCompletedNCT02230553Phase 1/2
• Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLCCompletedNCT02039336Phase 1/2